How orphan drug status and patent protection shape Ampligen’s commercial and regulatory outlook
Discover how orphan drug status and long-dated patents could shape Ampligen’s regulatory path and commercial value in pancreatic cancer.
How a proenzyme-based approach from Propanc Biopharma tests the limits of current solid tumor paradigms
Can a proenzyme therapy reshape solid tumor treatment models? Explore what Propanc Biopharma’s PRP strategy signals for oncology markets.
Is mutant-selective JAK2 inhibition ready for clinical reality after Prelude Therapeutics’ FDA IND clearance?
Prelude Therapeutics gains FDA IND clearance for PRT12396. Read how mutant-selective JAK2 inhibition could reshape MPN drug development.
Can oral NMDA blockers like Ketamir-2 disrupt current off-label CIPN treatments?
Find out how MIRA Pharmaceuticals’ Ketamir-2 aims to disrupt CIPN care with oral NMDA therapy as the company targets Fast Track and prepares for Phase 2a trials.
How SC-dosed NK cell engagers like GTB-5550 could disrupt cancer care delivery models
GT Biopharma’s GTB-5550 receives FDA clearance with subcutaneous delivery. See how this trial could shift NK immunotherapy into outpatient cancer care.
Is co-administered COVID prophylaxis with antibodies and mRNA vaccines the next FDA-backed model?
Invivyd’s LIBERTY trial explores co-administered COVID prevention with VYD2311 and mRNA vaccines. See how this could influence FDA and payer strategies.
Is viral vector therapy finally gaining traction in chemotherapy-resistant pediatric tumors?
Theriva’s APAO 2026 data shows viral–chemotherapy synergy in eye tumors. Find out what VCN-01 signals for pediatric oncology's biologics future.
Brand Engagement Network exits $50m equity line to reset dilution profile and capital discipline (NASDAQ: BNAI)
Brand Engagement Network has terminated a $50M equity line to cut dilution risk. Find out how this move could reshape investor sentiment and AI execution.
How Teads’ Google TV HomeScreen expansion could reshape premium CTV demand economics
Discover how Teads’ partnership with Google TV expands premium HomeScreen CTV advertising and what it means for global brand strategy today.
ETHZilla Corporation acquires $4.7M manufactured home loan portfolio to advance real-world asset tokenization strategy (NASDAQ: ETHZ)
Find out how ETHZilla Corporation’s $4.7M manufactured housing loan deal could reshape yield-backed real-world asset tokenization strategies.